UBS Group’s BiomX PHGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-573
| Closed | -$2.15K | – | 10890 |
|
|
2026
Q1 | $2.15K | Sell |
573
-1,706
| -75% | -$8.05K | ﹤0.01% | 9344 |
|
|
2025
Q4 | $4.26K | Buy |
2,279
+2,150
| +1,667% | +$14.5K | ﹤0.01% | 8862 |
|
|
2025
Q3 | $1.28K | Buy |
+129
| New | +$1.19K | ﹤0.01% | 9386 |
|
|
2025
Q2 | – | Sell |
-395
| Closed | -$4.18K | – | 10698 |
|
|
2025
Q1 | $4.18K | Buy |
+395
| New | +$5.51K | ﹤0.01% | 9142 |
|
|
2024
Q4 | – | Sell |
-199
| Closed | -$3.86K | – | 10276 |
|
|
2024
Q3 | $3.86K | Sell |
199
-58
| -23% | -$2.1K | ﹤0.01% | 8212 |
|
|
2024
Q2 | $16.4K | Buy |
+257
| New | +$17.3K | ﹤0.01% | 7435 |
|
|
2024
Q1 | – | Sell |
-11
| Closed | -$560 | – | 9853 |
|
|
2023
Q4 | $560 | Buy |
11
+10
| +1,000% | +$629 | ﹤0.01% | 8589 |
|
|
2023
Q3 | $37 | Buy |
+1
| New | +$74 | ﹤0.01% | 9051 |
|
|
2023
Q2 | – | Sell |
-16
| Closed | -$916 | – | 9463 |
|
|
2023
Q1 | $916 | Sell |
16
-141
| -90% | -$8.91K | ﹤0.01% | 8875 |
|
|
2022
Q4 | $5.68K | Buy |
157
+137
| +685% | +$7.55K | ﹤0.01% | 9142 |
|
|
2022
Q3 | $1K | Sell |
20
-36
| -64% | -$4.59K | ﹤0.01% | 10007 |
|
|
2022
Q2 | $8K | Buy |
56
+48
| +600% | +$9.86K | ﹤0.01% | 8332 |
|
|
2022
Q1 | $3K | Sell |
8
-30
| -79% | -$8.92K | ﹤0.01% | 9470 |
|
|
2021
Q4 | $12K | Buy |
38
+35
| +1,167% | +$14K | ﹤0.01% | 8571 |
|
|
2021
Q3 | $2K | Sell |
3
-71
| -96% | -$55K | ﹤0.01% | 8977 |
|
|
2021
Q2 | $77K | Buy |
74
+67
| +957% | +$77.9K | ﹤0.01% | 6075 |
|
|
2021
Q1 | $10K | Buy |
+7
| New | +$9.47K | ﹤0.01% | 7935 |
|
|
2020
Q4 | – | Sell |
-12
| Closed | -$14K | – | 8652 |
|
|
2020
Q3 | $14K | Buy |
12
+2
| +20% | +$2.23K | ﹤0.01% | 6591 |
|
|
2020
Q2 | $10K | Buy |
+10
| New | +$11.1K | ﹤0.01% | 7019 |
|
Other funds holding PHGE
UBS Group's PHGE Position: Q2 2026 in Review
UBS Group sold out of BiomX (PHGE) in Q2 2026, closing a stake of 573 shares — an estimated $2.15K sold.
UBS Group first reported a position in PHGE in Q2 2020 and held it in 19 quarters. The position peaked at $77K in Q2 2021. 6 funds tracked by Wall St. Rank hold PHGE as of Q2 2026.
- UBS Group reported no remaining BiomX position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 573 BiomX shares in Q2 2026, an estimated $2.15K.
- UBS Group first reported a position in BiomX in Q2 2020 and held it in 19 quarters.
- UBS Group's BiomX position peaked at $77K in Q2 2021.
- 6 funds tracked by Wall St. Rank held BiomX as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.